U.S. markets closed
  • S&P 500

    3,901.82
    +90.67 (+2.38%)
     
  • Dow 30

    31,535.51
    +603.14 (+1.95%)
     
  • Nasdaq

    13,588.83
    +396.48 (+3.01%)
     
  • Russell 2000

    2,275.32
    +74.27 (+3.37%)
     
  • Crude Oil

    60.33
    -0.31 (-0.51%)
     
  • Gold

    1,720.50
    -2.50 (-0.15%)
     
  • Silver

    26.58
    -0.10 (-0.37%)
     
  • EUR/USD

    1.2051
    -0.0036 (-0.30%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • GBP/USD

    1.3925
    +0.0003 (+0.02%)
     
  • USD/JPY

    106.8130
    +0.3110 (+0.29%)
     
  • BTC-USD

    49,482.46
    +4,300.41 (+9.52%)
     
  • CMC Crypto 200

    982.63
    +54.40 (+5.86%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Adaptive Bio Launches T-Cell Based COVID-19 Tests

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Adaptive Biotechnologies Corp (NASDAQ: ADPT) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection.

  • T-Detect is currently under review by the FDA for Emergency Use Authorization.

  • Separately, the Company also expanded its collaboration with Laboratory Corp. of America Holdings (NYSE: LH), which includes a commercial agreement for Adaptive's clonoSEQ and immunoSEQ assays, and a lab services agreement for Adaptive's recently launched T-Detect COVID test.

  • As part of the expanded pact, patients can now have blood collection for both the clonoSEQ and T-Detect COVID tests at any Lab Corp patient service centers.

  • Lab Corp will also offer immunoSEQ and immunoSEQ T-MAP COVID assays using Research Use Only test kits.

  • Price Action: LH is up 1.3% at $247.24, while ADPT is down 4.20% at $54.34 in market trading hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.